Clinical Trial Update: Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bendamustine in patients with refractory or relapsed T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: T-cell Lymphoma | Phase 2 | Status: COMPLETED